- Home
- IBRX vs DAC Comparison
IBRX vs DAC Comparison
Compare IBRX & DAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- DAC
- Stock Information
- Founded
- IBRX 2014
- DAC 1972
- Country
- IBRX United States
- DAC Greece
- Employees
- IBRX N/A
- DAC N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- DAC Marine Transportation
- Sector
- IBRX Health Care
- DAC Consumer Discretionary
- Exchange
- IBRX Nasdaq
- DAC Nasdaq
- Market Cap
- IBRX 1.9B
- DAC 1.6B
- IPO Year
- IBRX N/A
- DAC 2006
- Fundamental
- Price
- IBRX $2.94
- DAC $77.50
- Analyst Decision
- IBRX Strong Buy
- DAC Strong Buy
- Analyst Count
- IBRX 3
- DAC 1
- Target Price
- IBRX $13.58
- DAC $105.00
- AVG Volume (30 Days)
- IBRX 6.3M
- DAC 115.2K
- Earning Date
- IBRX 11-12-2024
- DAC 02-11-2025
- Dividend Yield
- IBRX N/A
- DAC 4.20%
- EPS Growth
- IBRX N/A
- DAC 0.27
- EPS
- IBRX N/A
- DAC 28.90
- Revenue
- IBRX $7,332,000.00
- DAC $1,005,246,000.00
- Revenue This Year
- IBRX $2,515.60
- DAC $1.25
- Revenue Next Year
- IBRX $766.19
- DAC $5.60
- P/E Ratio
- IBRX N/A
- DAC $2.68
- Revenue Growth
- IBRX 1218.71
- DAC 2.92
- 52 Week Low
- IBRX $2.28
- DAC $69.33
- 52 Week High
- IBRX $10.53
- DAC $98.25
- Technical
- Relative Strength Index (RSI)
- IBRX 48.30
- DAC 42.19
- Support Level
- IBRX $2.28
- DAC $77.37
- Resistance Level
- IBRX $2.54
- DAC $81.50
- Average True Range (ATR)
- IBRX 0.25
- DAC 1.88
- MACD
- IBRX 0.10
- DAC -0.08
- Stochastic Oscillator
- IBRX 64.71
- DAC 2.19
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About DAC Danaos Corporation
Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include, HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia-Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.